Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (20)
  • Open Access

    ARTICLE

    CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

    KAIWEN TIAN#, HANZHONG CHEN#, QIANQIAN WANG, FENGLIAN JIANG, CHUNXIANG FENG, TENG LI, XIAOYONG PU, YANLIN TANG*, JIUMIN LIU*

    BIOCELL, Vol.48, No.5, pp. 817-834, 2024, DOI:10.32604/biocell.2024.048737

    Abstract Background: The incidence of clear cell renal cell carcinoma (ccRCC) is globally high; however, despite the introduction of innovative drug therapies, there remains a lack of effective biomarkers for evaluating treatment response. Recently, Caspase recruiting domain-containing protein 11 (CARD11) has garnered attention due to its significant association with tumor development and the immune system. Methods: The expression of CARD11 mRNA and protein in ccRCC were analyzed by public database and immunohistochemistry. The focus of this study is on the epigenomic modifications of CARD11, its expression of ccRCC immunophenotype, and its correlation with response to immunotherapy… More > Graphic Abstract

    CARD11 serves as a therapeutic biomarker for the drug therapies of ccRCC

  • Open Access

    ARTICLE

    Using MsfNet to Predict the ISUP Grade of Renal Clear Cell Carcinoma in Digital Pathology Images

    Kun Yang1,2,3, Shilong Chang1, Yucheng Wang1, Minghui Wang1, Jiahui Yang1, Shuang Liu1,2,3, Kun Liu1,2,3, Linyan Xue1,2,3,*

    CMC-Computers, Materials & Continua, Vol.78, No.1, pp. 393-410, 2024, DOI:10.32604/cmc.2023.044994

    Abstract Clear cell renal cell carcinoma (ccRCC) represents the most frequent form of renal cell carcinoma (RCC), and accurate International Society of Urological Pathology (ISUP) grading is crucial for prognosis and treatment selection. This study presents a new deep network called Multi-scale Fusion Network (MsfNet), which aims to enhance the automatic ISUP grade of ccRCC with digital histopathology pathology images. The MsfNet overcomes the limitations of traditional ResNet50 by multi-scale information fusion and dynamic allocation of channel quantity. The model was trained and tested using 90 Hematoxylin and Eosin (H&E) stained whole slide images (WSIs), which… More >

  • Open Access

    ARTICLE

    Aryl hydrocarbon receptor nuclear translocator 2 as a prognostic biomarker and immunotherapeutic indicator for clear cell renal cell carcinoma

    RENLONG ZHOU1,2,#, SHUANG LI3,#, XILIN XIAO1,*

    BIOCELL, Vol.47, No.11, pp. 2397-2408, 2023, DOI:10.32604/biocell.2023.030281

    Abstract Background: In many cancer types, aryl hydrocarbon receptor nuclear translocator 2 (ARNT2) has been found to be associated with tumor cell proliferation and prognosis. However, the role of ARNT2 in clear cell renal cell carcinoma (ccRCC) has not been completely elucidated. In this study, the potential role of ARNT2 in ccRCC development was characterized. Methods: A pan-cancer dataset (TCGA-TARGET-GTEx) was accessed from UCSC Xena Data Browser. ARNT2 expression in normal and tumor samples was compared. Univariate Cox regression was performed to evaluate the prognostic value of ARNT2. Single sample gene set enrichment analysis (ssGSEA) was… More >

  • Open Access

    REVIEW

    Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

    WENFEI GE1,#, SHIYAN SONG1,#, XIAOCHEN QI1,#, FENG CHEN1,#, XIANGYU CHE1, YONGHAO SUN1, JIN WANG1, XIAOWEI LI2, NANA LIU3, QIFEI WANG1,*, GUANGZHEN WU1,*

    Oncology Research, Vol.31, No.3, pp. 255-270, 2023, DOI:10.32604/or.2023.027942

    Abstract As a common tumor of the urinary system, the morbidity and mortality related to renal carcinoma, are increasing annually. Clear cell renal cell carcinoma (CCRCC) is the most common subtype of renal cell carcinoma, accounting for approximately 75% of the total number of patients with renal cell carcinoma. Currently, the clinical treatment of ccRCC involves targeted therapy, immunotherapy, and a combination of the two. In immunotherapy, PD-1/PD-L1 blocking of activated T cells to kill cancer cells is the most common treatment. However, as treatment progresses, some patients gradually develop resistance to immunotherapy. Meanwhile, other patients More > Graphic Abstract

    Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

  • Open Access

    ARTICLE

    Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma

    WEI BAO1,#, QIANGUANG HAN2,#, XIAO GUAN3, ZIJIE WANG2, MIN GU1,2,*

    Oncology Research, Vol.31, No.2, pp. 181-192, 2023, DOI:10.32604/or.2023.028051

    Abstract Background: Clear-cell renal cell carcinoma (ccRCC) is the most common malignant kidney cancer. However, the tumor microenvironment and crosstalk involved in metabolic reprogramming in ccRCC are not well-understood. Methods: We used The Cancer Genome Atlas to obtain ccRCC transcriptome data and clinical information. The E-MTAB-1980 cohort was used for external validation. The GENECARDS database contains the first 100 solute carrier (SLC)-related genes. The predictive value of SLC-related genes for ccRCC prognosis and treatment was assessed using univariate Cox regression analysis. An SLC-related predictive signature was developed through Lasso regression analysis and used to determine the risk… More >

  • Open Access

    ARTICLE

    Differentiate Xp11.2 Translocation Renal Cell Carcinoma from Computed Tomography Images and Clinical Data with ResNet-18 CNN and XGBoost

    Yanwen Lu1,#, Wenliang Ma1,#, Xiang Dong1,#, Mackenzie Brown2, Tong Lu3,*, Weidong Gan1,*

    CMES-Computer Modeling in Engineering & Sciences, Vol.136, No.1, pp. 347-362, 2023, DOI:10.32604/cmes.2023.024909

    Abstract This study aims to apply ResNet-18 convolutional neural network (CNN) and XGBoost to preoperative computed tomography (CT) images and clinical data for distinguishing Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) from common subtypes of renal cell carcinoma (RCC) in order to provide patients with individualized treatment plans. Data from 45 patients with Xp11.2 tRCC from January 2007 to December 2021 are collected. Clear cell RCC (ccRCC), papillary RCC (pRCC), or chromophobe RCC (chRCC) can be detected from each patient. CT images are acquired in the following three phases: unenhanced, corticomedullary, and nephrographic. A unified framework More >

  • Open Access

    ARTICLE

    A developed ant colony algorithm for cancer molecular subtype classification to reveal the predictive biomarker in the renal cell carcinoma

    ZEKUN XIN1,#, YUDAN MA2,#, WEIQIANG SONG3, HAO GAO3, LIJUN DONG3, BAO ZHANG1,*, ZHILONG REN3,*

    BIOCELL, Vol.47, No.3, pp. 555-567, 2023, DOI:10.32604/biocell.2023.026254

    Abstract Background: Recently, researchers have been attracted in identifying the crucial genes related to cancer, which plays important role in cancer diagnosis and treatment. However, in performing the cancer molecular subtype classification task from cancer gene expression data, it is challenging to obtain those significant genes due to the high dimensionality and high noise of data. Moreover, the existing methods always suffer from some issues such as premature convergence. Methods: To address those problems, we propose a new ant colony optimization (ACO) algorithm called DACO to classify the cancer gene expression datasets, identifying the essential genes of… More >

  • Open Access

    ARTICLE

    Macrophage-derived exosomal miR-342-3p promotes the progression of renal cell carcinoma through the NEDD4L/CEP55 axis

    JIAFU FENG1,2,#,*, BEI XU1,2,#, CHUNMEI DAI1,2,#, YAODONG WANG1,4, GANG XIE1,5, WENYU YANG1,2, BIN ZHANG1,2, XIAOHAN LI6, JUN WANG3

    Oncology Research, Vol.29, No.5, pp. 331-349, 2021, DOI:10.32604/or.2022.03554

    Abstract Due to its difficulty in early diagnosis and lack of sensitivity to chemotherapy and radiotherapy, renal cell carcinoma (RCC) remains to be a frequent cause of cancer-related death. Here, we probed into new targets for its early diagnosis and treatment for RCC. microRNA (miRNA) data of M2-EVs and RCC were searched on the Gene Expression Omnibus database, followed by the prediction of the potential downstream target. Expression of target genes was measured via RT-qPCR and Western blot, respectively. M2 macrophage was obtained via flow cytometry with M2-EVs extracted. The binding ability of miR-342-3p to NEDD4L… More >

  • Open Access

    ARTICLE

    RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma

    DAWEI ZHU1,#, LEI ZHANG1,#, XIAOKAI SHI1, SHENGLIN GAO1, CHUANG YUE1, LIFENG ZHANG1, YU BAI1, QIFENG WANG2, ATSUSHI OKADA3, TAKAHIRO YASUI3, CHAO WANG1,4, XINGANG CUI4,5,*, LI ZUO1,*

    Oncology Research, Vol.29, No.3, pp. 159-174, 2021, DOI:10.32604/or.2022.03458

    Abstract Identifying prognostic indicators of clear cell renal cell carcinoma (ccRCC) and elucidating the mechanisms underlying ccRCC progression are crucial for improving ccRCC patient prognosis. This study investigated the clinical significance and biological role of Ring finger protein 43 (RNF43) in ccRCC. Two independent cohorts of patients with ccRCC were employed to determine the prognostic significance of RNF43 by immunohistochemistry and statistical analyses. In vitro and in vivo experiments, RNA-seq, and other techniques were used to determine the biological role of RNF43 in ccRCC and related molecular mechanisms. RNF43 expression was commonly decreased in ccRCC specimens, and low… More >

  • Open Access

    ARTICLE

    The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma

    Dayu Tian1, Yang Shi1, Li Lei1, Xiangmin Qiu1, Tao Song2,*, Qianyin Li1,*

    Oncologie, Vol.24, No.2, pp. 261-282, 2022, DOI:10.32604/oncologie.2022.022838

    Abstract Background: Six2, a transcription factor, exerts an oncogenic role in clear cell renal cell carcinoma (ccRCC). Increased Six2 expression could enhance cancer metastasis. However, the regulatory mechanism of Six2 in promoting metastasis remains unclear. The purpose of this study is to analyze the regulatory pattern of Six2 and the potential role of Six2 in the tumor immune microenvironment. Materials and Methods: Firstly, transcriptional data in TCGA-KIRC cohorts was used to analyze the relationship between Six2 expression and clinical information. Secondly, we detect the association between Six2 and the tumor immune microenvironment in ccRCC. Then, we analyzed Six2-related… More >

Displaying 1-10 on page 1 of 20. Per Page